ArticleBMC cancer2026
Betel nut chewing influences pathologic response in oral squamous cell carcinoma treated by neoadjuvant immunochemotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBetel nut chewing (BNC) is a prevalent risk factor for oral squamous cell carcinoma (SCC) in South and Southeast Asia, yet its influence on response to neoadjuvant immunochemotherapy remains unexplored. This study aimed to evaluate the association between BNC and pathologic response in oral SCC patients receiving neoadjuvant immunochemotherapy.
methodsWe retrospectively reviewed 192 patients with primary oral SCC who received neoadjuvant immunochemotherapy (docetaxel, cisplatin, and PD-1 inhibitors) followed by surgery between January 2020 and October 2024. Pathologic complete response (pCR), major pathologic response (mPR), objective response rate (ORR), clinical to pathological downstaging, adverse pathologic features, and disease-free survival (DFS) were compared between BNC (n = 42) and no-BNC (n = 150) groups.
resultsBNC patients demonstrated significantly lower pCR (16.7% vs. 34.0%; OR = 2.55, p = 0.031) and mPR rates (54.8% vs. 74.7%; OR = 3.17, p = 0.013) compared to no-BNC patients. Multivariable analysis confirmed absence of BNC as an independent predictor of both pCR (adjusted OR = 2.55, 95% CI: 1.20-7.65) and mPR (adjusted OR = 3.17, 95% CI: 1.32-8.53). BNC was also associated with lower ORR (73.8% vs. 86.7%, p = 0.045), reduced downstaging (71.4% vs. 90.0%, p = 0.002), and higher prevalence of adverse pathologic features (19.0% vs. 4.7%, p = 0.005). The poorest outcomes occurred in well/moderately differentiated tumors with BNC history. BNC did not significantly impact DFS (3-year DFS: 71.2% vs. 78.4%, p = 0.194). Number of neoadjuvant cycles did not influence pathologic response.
conclusionsBNC is an independent predictor of suboptimal pathologic response to neoadjuvant immunochemotherapy in oral SCC, although it does not adversely affect DFS. These findings may inform patient selection and treatment stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.